LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/John Nosenzo New Chief Commercial Officer at Bioventus
People In The News

John Nosenzo New Chief Commercial Officer at Bioventus

January 27, 2017 2 min read Premium comments

Advertisement

John Nosenzo New Chief Commercial Officer at Bioventus
John Nosenzo

John Nosenzo has been named Chief Commercial Officer of Bioventus, an orthobiologic company headquartered in Durham, North Carolina. According to the January 23, 2017 news release, “Nosenzo brings more than 25 years of progressive sales and marketing leadership in pharmaceuticals and medical diagnostic markets to the company. He will be responsible for leading all global sales and distributor management functions for Bioventus, as well as global marketing for the Active Healing Therapies business, and the key customer interface functions responsible for expanding market access for our products and for providing reimbursement services for the EXOGEN Ultrasound Bone Healing System.”

“Prior to joining Bioventus, Nosenzo was Senior Vice President, Global Customer Operations at Beckman Coulter Diagnostics since 2011. Previously, he was Senior Vice President, Customer Relations Management for Siemens Healthcare, and Vice President, Marketing and Sales at Quest Diagnostics. He earned an MBA in marketing and management from Adelphi University and a Bachelor of Science in pharmacy from St. John’s University.”

“John is a natural charismatic leader who develops top talent, builds strong teams, and consistently delivers exceptional sales results, ” said Tony Bihl. “We are very pleased he is joining us to lead our commercial organization and look forward to the impact he will make with our customers and our commercial team and processes, to fully capture the global market potential for Bioventus’ expanding product portfolio.”

Nosenzo told OTW, “I have had the privilege to work in the healthcare industry my entire life. First, as a pharmacist and then in commercial roles in both pharmaceutical and diagnostic healthcare companies. I believe my past 30 years of global commercial experience has been the best preparation for this role. During those years I have had the opportunity to hold virtually every role in a commercial organization including sales, service, marketing, training and a variety of global commercial management positions. These assignments have allowed me to understand the importance of each role and the skills needed to be successful. Additionally, the experience has allowed me to develop strong marketing and business development skills. Most importantly, I never forget that the patient is the reason we do what we do. Serving our physicians and ultimately their patients has been driver for me.”

“As I prepare for my first day I am already immersing myself in understanding our products and technology. Once officially onboard, my first step will be to get to know my direct team, the customer-facing organization and our customers. I believe a customer centric commercial organization is a critical key to success. My plan is to spend a good deal of my early days in the field with our sales team meeting with customers. Our customers and their patients are the foundation of Bioventus so getting to know them and understanding their needs will be a high priority for me.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy